Abstract:RationaleProteomics and metabolomics are widely used in the study of diabetes, but rarely in prediabetes research. This study aimed to explore the mechanisms of early-onset type 2 diabetes mellitus (T2DM) by analyzing proteomic changes at different stages of glucose metabolism. MethodsA total of 40 individuals undergoing routine physical health examinations between December 2016 and April 2017 were enrolled. Subjects were divided into four groups based on fasting blood glucose (FPG) levels: FPG < 5.6 mmol/L (group A); FPG >= 5.6 mmol/L and <6.1 mmol/L (group B); FPG >= 6.1 mmol/L and <7.0 mmol/L (group C); and FPG >= 7.0 mmol/L (group D). Each group had 10 cases. Sera from these 40 subjects were analyzed by label-free quantitative liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS). LC/MS/MS with selected reaction monitoring mode was also performed for qualitative and quantitative metabolomics analysis. Differentially expressed proteins were identified. Partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were used to analyze the differentially expressed metabolites. ResultsA total of 202 differentially expressed proteins were screened and were identified as mainly secreted proteins. Comparing group A with group B, 32 proteins were up-regulated and 18 proteins were down-regulated. Comparing group A with group C, 24 proteins were up-regulated and 24 proteins were down-regulated. Comparing group A with group D, 19 proteins were up-regulated and 17 proteins were down-regulated. The fold change for up-regulated proteins was >1.2, p < 0.05, while the fold change for down-regulated proteins was <-1.2, p < 0.05. PLS-DA and OPLS-DA revealed 113 differentially expressed metabolites. Correlation analysis of differentially expressed metabolites of group A versus group B revealed that among the down-regulated differential proteins, transforming growth factor beta-induced protein ig-h3 correlated negatively with metabolite L-saccharin, while among the up-regulated differential proteins, apolipoprotein C-IV correlated negatively with metabolite 3-methyloxindole. Among all differentially expressed proteins, 19 proteins were associated with early initiation of chronic inflammation, including CD14 and CSF-1R, which were newly identified in the early onset of T2DM. ConclusionsMany proteins are differentially expressed between prediabetes and after T2DM diagnosis, although the specific mechanism remains unclear. The expression level of CD14 was significantly up-regulated and that of CSF-1R was significantly down-regulated when FPG was >= 5.6 mmol/L, suggesting that CD14 and CSF-1R may be important markers for early-onset T2DM and may serve as new targets for T2DM treatment.

Lower Serum Branched-Chain Amino Acid Catabolic Intermediates Are Predictive Signatures Specific to Patients with Diabetic Foot.

Lower serum branched-chain amino acid catabolic intermediates are predictive signatures specific to diabetic foot patients

Analysis of Protein Expression Changes in Patients with Prediabetes Using Proteomics Approaches.

Serum Metabolite Signatures of Type 2 Diabetes Mellitus Complications.

Diabetic foot exacerbates gut mycobiome dysbiosis in adult patients with type 2 diabetes mellitus: revealing diagnostic markers

Tandem Mass Tag-Based Serum Proteomic Profiling Revealed Diabetic Foot Ulcer Pathogenesis and Potential Therapeutic Targets

Targeted Metabolomics Analysis of Serum Amino Acids in T2DM Patients

Analysis Of Serum Metabolomics Among Biopsy-Proven Diabetic Nephropathy, Type 2 Diabetes Mellitus And Healthy Controls

Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients.

Serum branched chain amino acids: an effective indicator of diabetic kidney disease

Serum bile acid and unsaturated fatty acid profiles of non-alcoholic fatty liver disease in type 2 diabetic patients

Serum Metabolic Signatures of Subclinical Atherosclerosis in Patients with Type 2 Diabetes Mellitus: a Preliminary Study

Serum Metabolomic Analysis Revealed Potential Metabolite Biomarkers for Diabetes Mellitus with Coronary Heart Disease

Plasma Targeted Metabolomics Analysis for Amino Acids and Acylcarnitines in Patients with Prediabetes, Type 2 Diabetes Mellitus, and Diabetic Vascular Complications

Untargeted and Targeted Lipidomics Unveil Dynamic Lipid Metabolism Alterations in Type 2 Diabetes

Machine Learning Reveals Metabolic Signatures in Patients with Type 1 Diabetes

The Metabolic Characteristics of Patients at the Risk for Diabetic Foot Ulcer: A Comparative Study of Diabetic Patients with and without Diabetic Foot

Impaired Amino Acid Metabolism and Its Correlation with Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus

Identification of potential biomarkers for diabetic cardiomyopathy using LC-MS-based metabolomics

Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study